Galectin Therapeutics (GALT) Misses Q1 EPS by 2c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• HP Inc. projects mid-single-digit PC market decline in 2027
• RBC Capital Starts Tabcorp Holdings (TAH:AU) (TABCF) at Outperform